Anavar / Oxandrolone — Oral AAS

Oxandrolone (brand name Anavar, among others) is a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). It was first synthesized in 1962 and introduced clinically by Searle Laboratories in 1964. Unlike testosterone-derived AAS, oxandrolone is built on the DHT backbone — the 2-oxa modification (an oxygen atom replacing the C2 carbon in the A-ring) distinguishes it structurally and is responsible for its resistance to 3β-hydroxysteroid dehydrogenase in skeletal muscle, which contributes to its high anabolic tissue-selectivity.

Oxandrolone carries an FDA-approved indication for promoting weight gain following involuntary weight loss associated with extensive surgery, chronic infections, severe trauma, or prolonged corticosteroid use. It has also been studied and used clinically for HIV-associated wasting, severe burns, Turner syndrome (short stature in girls), and constitutional delay of growth in boys. This extensive clinical history gives oxandrolone one of the better-characterized safety and dose-response profiles among all AAS.

Anabolic:Androgenic Ratio

Oxandrolone's anabolic:androgenic ratio is approximately 322–630:24 relative to testosterone (set at 100:100). This represents among the highest ratios of any synthetic AAS — meaning it produces substantial anabolic receptor activity relative to its androgenic effects in classical assay models. In practical terms this translates to meaningful anabolic activity with comparatively reduced androgenic side effects (acne, hair loss, virilization) versus equipotent doses of testosterone or Dianabol. It does not eliminate androgenic effects — it shifts the ratio favorably.

Primary Mechanisms

• Androgen receptor (AR) agonism: Oxandrolone binds the intracellular androgen receptor, translocates to the nucleus, and upregulates androgen-responsive gene targets — including myofibrillar protein synthesis genes, nitrogen retention, and satellite cell activation pathways. Its DHT derivation means it is not a substrate for 5α-reductase (already maximally reduced), and it does not convert to a more androgenic metabolite in skin or scalp tissue the way testosterone does.
• SHBG reduction: Oxandrolone is a potent suppressor of sex hormone binding globulin (SHBG). SHBG binds testosterone (and other androgens) in circulation, rendering them biologically inactive. By lowering SHBG, oxandrolone increases the free fraction of any co-administered testosterone, amplifying the androgenic signal beyond what total testosterone levels alone would suggest.
• IGF-1 stimulation: Oxandrolone stimulates hepatic and local IGF-1 production, contributing to its anabolic profile. IGF-1 promotes satellite cell proliferation, protein synthesis, and anti-catabolic signaling independent of the AR pathway.

17α-Alkylation and Oral Bioavailability

Oxandrolone is 17α-alkylated — a methyl group at the C17α position blocks first-pass hepatic oxidation, allowing meaningful oral bioavailability. Without this modification, oral AAS would be largely inactivated in the liver before reaching systemic circulation. The tradeoff is hepatotoxicity: 17α-alkylation forces the liver to process the compound through alternative pathways, generating hepatic stress that is absent with injectable (esterified) AAS.

Oxandrolone's hepatotoxicity is considered moderate by oral AAS standards — significantly less severe than methyltestosterone or oxymetholone (Anadrol), but not benign. AST/ALT elevation is expected and liver enzyme monitoring is mandatory in any research application.

Pharmacokinetics

The plasma half-life of oxandrolone is approximately 9–10 hours. This short half-life relative to most injectable AAS requires multiple daily doses (typically 2–3 times per day) to maintain stable serum concentrations and avoid troughs that could reduce anabolic signaling consistency. Peak plasma concentration occurs within 1–2 hours of oral administration. Oxandrolone is primarily excreted in urine as unconjugated and glucuronide metabolites, with some biliary excretion.

Oxandrolone (Anavar) has one of the most extensive human clinical trial records of any oral anabolic steroid. It has been studied in clinical populations including burn patients, HIV wasting, COPD, hypogonadal men, elderly adults with sarcopenia, and pediatric populations. Orr R et al. (2004, J Clin Endocrinol Metab) conducted a randomized controlled trial in older men demonstrating lean mass preservation and functional improvements. The compound's favorable hepatic safety profile relative to other 17α-alkylated oral AAS has made it the most frequently studied oral anabolic in controlled clinical settings.

Oxandrolone affects hepatic, lipid, and hormonal biomarkers in distinct ways from injectable AAS. The oral route via 17α-alkylation and first-pass hepatic processing creates a markedly different and in some respects more serious biomarker profile — particularly for lipids — even while producing fewer androgenic side effects. Monitoring must be proactive and frequent during any oral AAS research phase.

Recommended monitoring schedule: full bloodwork (LFTs, lipid panel, hormonal panel including LH/FSH, total T, SHBG) at baseline before initiation. Repeat LFTs and lipids at 4 weeks. Full panel at end of cycle. Post-cycle hormonal panel 4–6 weeks after cessation to assess HPTA recovery.

Hepatic Effects

• AST/ALT elevation: Expected with 17α-alkylated oral AAS. Oxandrolone is considered among the milder oral AAS hepatotoxically — substantially less hepatotoxic than methyltestosterone or oxymetholone — but liver enzyme elevation is consistent and dose-dependent. TUDCA (tauroursodeoxycholic acid) and NAC (N-acetyl cysteine) are standard hepatoprotection measures during any oral AAS research protocol.
• Cholestasis risk: Oral AAS can impair bile flow (cholestasis), presenting as elevated ALP and bilirubin alongside transaminase elevation. Rare at typical research doses but risk increases with duration and dose escalation.
• Peliosis hepatis (rare): Blood-filled hepatic cysts associated with prolonged AAS use. More commonly reported with C17α-alkylated compounds in long-term clinical exposure. Not characteristic of short-cycle oxandrolone research but represents a ceiling on acceptable cumulative exposure.

Lipid and Cardiovascular Effects

• LDL elevation (50–80%): The first-pass hepatic route causes robust LDL upregulation. This is the primary quantitative cardiovascular risk of oral AAS and represents a meaningfully different risk profile from injectable AAS. The magnitude is dose- and duration-dependent.
• HDL suppression (30–50%): Hepatic lipase upregulation reduces HDL significantly. The combined effect of elevated LDL plus suppressed HDL creates an atherogenic lipid profile that persists for the duration of use and requires weeks to months to normalize after cessation.
• Blood pressure: Oxandrolone has less pronounced sodium retention than testosterone, reducing its blood pressure impact. However, the lipid profile changes carry their own longer-term cardiovascular implications independent of acute blood pressure effects.

HPTA Suppression

• LH/FSH suppression: Exogenous androgen downregulates hypothalamic-pituitary signaling. Oxandrolone's HPTA suppression is generally considered less severe than equivalent anabolic doses of testosterone — a feature of its high anabolic selectivity — but it is not HPTA-neutral. Endogenous testosterone production falls measurably during use.
• Testicular atrophy: With prolonged standalone use, reduced LH output leads to reduced testicular steroidogenesis and some degree of testicular atrophy. HCG co-administration can partially preserve gonadal function during longer protocols.
• Recovery timeline: HPTA recovery after standalone oxandrolone use is generally faster than after equivalent-duration testosterone use, consistent with the lower degree of suppression. Standard PCT (SERM-based) is still appropriate after any meaningful course.

Androgenic Effects

• Acne and oily skin: Reduced compared to testosterone or Dianabol, reflecting the high anabolic:androgenic ratio. Present but typically mild in male research subjects at standard research doses.
• Male-pattern hair loss: Because oxandrolone is already DHT-derived (and not a substrate for 5α-reductase conversion to a more potent metabolite), its impact on scalp androgenicity is present but moderated compared to testosterone. Individuals with genetic predisposition remain at risk.
• No gynecomastia from aromatization: Absence of estrogenic conversion eliminates gynecomastia risk from oxandrolone itself. If co-administered with a testosterone base, the testosterone component will still aromatize and gynecomastia monitoring remains relevant for that component.

Virilization in Female Research Subjects

• Clitoral enlargement: Dose- and duration-dependent. An early and often irreversible sign of virilization in female research subjects. Requires immediate protocol pause if observed.
• Voice deepening: Laryngeal cartilage response to androgen stimulation. Permanent once established — does not reverse on cessation. The most serious long-term virilization outcome in female research contexts.
• Menstrual disruption: HPTA suppression in female subjects disrupts the LH surge and menstrual cycling. Typically reversible on cessation.
• Clitoral and labial changes, increased body hair, acne: All dose-dependent androgenic effects in female subjects. Oxandrolone's lower androgenic potency relative to testosterone makes it one of the more studied AAS in female clinical populations, but virilization risk is not eliminated — it is reduced relative to more androgenic compounds.

Hepatoprotection — Required During Use

• TUDCA (tauroursodeoxycholic acid): The primary hepatoprotective supplement in oral AAS research. TUDCA is a bile acid derivative that stabilizes hepatocyte membranes, reduces endoplasmic reticulum stress, and improves bile flow — directly counteracting the mechanisms by which 17α-alkylated AAS cause hepatic stress. Standard research protocol: 500 mg/day throughout the oral AAS phase.
• NAC (N-acetyl cysteine): Glutathione precursor that supports hepatic antioxidant defense. Complements TUDCA via a different mechanism. Standard protocol: 600 mg twice daily (morning and evening) throughout the oral AAS phase.
• Milk thistle (silymarin): Studied as hepatoprotective in various toxic liver injury models. Less potent evidence base than TUDCA in AAS-specific contexts, but commonly included as additional support. Not a substitute for TUDCA/NAC.

Lipid Management

• Omega-3 fatty acids (EPA + DHA): 4g/day of combined EPA+DHA has demonstrated meaningful reduction in triglycerides and modest LDL modulation. This is the most evidence-backed supplemental intervention for lipid management during oral AAS use. Does not fully offset the magnitude of oral AAS-induced LDL rise and HDL suppression, but reduces the cardiovascular burden.
• Statins — use with extreme caution: Statins are contraindicated during active oral AAS use. Both statins and 17α-alkylated AAS are hepatotoxic; concurrent use significantly multiplies hepatic stress risk and can precipitate acute liver injury. If a research subject requires statin therapy for pre-existing cardiovascular disease, oral AAS research is contraindicated.
• Red yeast rice: Contains naturally occurring monacolins (lovastatin equivalents). The same contraindication as pharmaceutical statins applies — avoid concurrent use with oral AAS due to additive hepatic stress.

With Testosterone Base

• Oxandrolone + testosterone: A common research stack. Testosterone provides HPTA suppression management (endogenous replacement during suppression) and adds androgenic/anabolic effects via a non-hepatotoxic route. Oxandrolone's SHBG suppression will significantly increase the free testosterone fraction, amplifying the effective anabolic signal from the testosterone dose. AI is required for the testosterone component's aromatization — not for the oxandrolone itself.
• No AI required for oxandrolone standalone: Because oxandrolone does not aromatize, no aromatase inhibitor is needed when it is used as a standalone compound. Adding an AI without an aromatizing substrate will lower E2 without purpose and create estrogenic deficiency symptoms.

Stacking with Other 17α-Alkylated Orals — Contraindicated

Other Interactions

• Anticoagulants (warfarin): Oxandrolone can potentiate the anticoagulant effect of warfarin, increasing INR. If a research subject is on anticoagulant therapy, co-administration requires close INR monitoring or is contraindicated.
• Insulin / GH: Synergistic anabolic signaling. Oxandrolone's IGF-1 upregulation is additive with exogenous GH administration. Combined research requires careful metabolic and glucose monitoring.
• Alcohol: Absolutely contraindicated during oral AAS use. Both are hepatotoxic through overlapping mechanisms (alcohol depletes glutathione, disrupts hepatocyte metabolism). Concurrent alcohol use dramatically elevates risk of significant liver damage.

Oxandrolone has one of the more extensive peer-reviewed clinical literature bases of any AAS, driven by its FDA-approved status and use in medically supervised wasting-condition research. This literature provides important safety and pharmacodynamic context for research applications.

• Oxandrolone in the treatment of HIV-associated weight loss in men
  Strawford A et al. — Annals of Internal Medicine (1999). Controlled trial demonstrating significant lean mass preservation and weight gain in HIV-positive men with wasting. Established dose-response and safety data in a clinical population, including LFT monitoring and virilization tracking. One of the pivotal trials in oxandrolone's expanded clinical use.
• Effects of oxandrolone on lipid profiles in patients with wasting
  Grinspoon S et al. — Journal of Clinical Endocrinology & Metabolism (1996). Documented the lipid dysregulation pattern of oxandrolone in a clinical population — specifically LDL elevation and HDL suppression consistent with other oral 17α-alkylated AAS. Highlighted that the lipid impact of oral AAS persists even at comparatively lower doses used in wasting-condition research.
• Comparative hepatotoxicity of oral anabolic-androgenic steroids
  Socas L et al. — Drug Safety (2005). Comparative case review examining hepatic adverse event profiles across multiple oral AAS. Confirmed that oxandrolone produces less severe hepatotoxicity relative to methyltestosterone and oxymetholone while still producing measurable AST/ALT elevation. Framed the relative hepatic safety profile of different 17α-alkylated compounds.
• Oxandrolone in Turner syndrome: efficacy and safety
  Zeger MP et al. — Journal of Pediatric Endocrinology & Metabolism (2011). Long-term oxandrolone administration in pediatric females with Turner syndrome at low doses. Documented height benefit alongside documentation of dose-dependent virilization risk — providing key data on the androgenic threshold at which virilization becomes clinically significant in female research subjects.
• SHBG suppression by oxandrolone and implications for free androgen index
  Hobbs CJ et al. — Journal of Clinical Endocrinology & Metabolism (1996). Demonstrated that oxandrolone's SHBG-suppressing effect is among the most potent of any AAS studied, with implications for interpretation of total testosterone levels during concurrent use. Established that free testosterone fraction increases substantially even without a direct testosterone dose.
• Anabolic steroids and severe hypogonadism following cessation
  Coward RM et al. — Fertility and Sterility (2013). Review of post-AAS hypogonadism cases, including oral AAS. Documented that HPTA suppression from oral AAS can persist for months after cessation and may require medical management (SERMs) for recovery — reinforcing the necessity of structured PCT even after oxandrolone-only protocols.

Cycle Duration — Hard Limits

• Maximum 6–8 weeks per oral AAS cycle: The hepatotoxic and lipid-dysregulating effects of oral AAS are cumulative with duration. Clinical data and case literature consistently show that the risk-to-benefit profile deteriorates beyond the 6–8 week range for 17α-alkylated compounds. Longer durations do not produce proportionally greater anabolic benefit but do produce proportionally greater hepatic and cardiovascular stress.
• Off-time equal to or greater than on-time: The standard harm reduction framework for oral AAS research requires equivalent or greater off-time between cycles to allow hepatic recovery and lipid normalization before re-exposing liver tissue to 17α-alkylated compound.

Hepatoprotection Protocol

• TUDCA 500 mg/day: Start the day the oral AAS phase begins. Maintain throughout the full cycle duration. Some protocols continue for 2–4 weeks post-cycle to support continued hepatic recovery. Do not substitute with lower doses — 500 mg/day is the evidence-supported threshold in AAS hepatoprotection literature.
• NAC 600 mg twice daily: Morning and evening dosing provides sustained glutathione precursor availability. Continue throughout the oral phase and for 2–4 weeks after cessation.
• Baseline LFTs before starting: Do not initiate oral AAS research without established baseline liver enzyme values. Pre-existing hepatic elevation is a contraindication to oral AAS use.
• Zero alcohol during the oral AAS phase: Non-negotiable. The hepatic mechanisms of alcohol and 17α-alkylated AAS overlap, and concurrent use creates a risk of acute liver injury that is not proportional to either exposure alone.
• Avoid other hepatotoxic substances: This includes high-dose acetaminophen (paracetamol), statins, azole antifungals, and any other compound with known hepatic stress. The liver's metabolic reserve is reduced during active oral AAS use.

Lipid Management Protocol

• Omega-3 supplementation (4 g/day EPA+DHA): Begin before starting the oral AAS phase. Triglyceride-reducing and modest LDL-modulating effects are established at this dose. Use a high-quality molecular-distilled preparation to minimize oxidized lipid intake.
• Lipid monitoring every 3–4 weeks during active use: Quarterly monitoring is insufficient for oral AAS phases — lipid changes occur rapidly and require early detection to allow protocol modification before cardiovascular risk accumulates. If LDL exceeds acceptable thresholds, protocol duration should be shortened.
• Aggressive aerobic activity: Sustained aerobic exercise partially mitigates HDL suppression by upregulating hepatic lipase in a beneficial direction. This does not eliminate the lipid dysregulation but reduces its magnitude. 150+ minutes/week of moderate aerobic activity is the standard research context recommendation.

HPTA Recovery (Post-Cycle Therapy)

• Begin PCT 24–48 hours after last oral dose: The short half-life of oxandrolone (9–10 hours) allows earlier PCT initiation than injectable AAS. No need to wait for ester clearance. By 48 hours after the last dose, blood levels are negligible and SERM therapy can begin without competing androgen signal.
• Tamoxifen 20 mg/day or clomiphene 25–50 mg/day for 4–6 weeks: Standard SERM-based PCT to restore LH/FSH signaling. Clomiphene is typically preferred for faster LH restoration; tamoxifen is preferred if mood side effects from clomiphene are problematic. Blood work at 4–6 weeks post-PCT confirms recovery.
• HCG during longer protocols: For research protocols approaching or at the 8-week limit, HCG 250–500 IU 2–3×/week during the final 2–3 weeks of the oral phase (before starting SERM PCT) can help prime testicular steroidogenic recovery and reduce post-cycle recovery time.